Functional Durability & T-Cell Exhaustion

• Exhaustion-related phenotypes: PD-1, TIM-3, LAG-3, TIGIT; TOX, TCF-1, CD127
• Functional durability: proliferation, cytokine production, and retained cytotoxicity after repeated stimulation

Experimental Design Highlights

Use extended co-culture (72–96 h) or a repeated-stimulation regimen (fresh target cells replenished every 48 h), then measure multiple inhibitory receptors on the T-cell surface and combine with functional assays to judge the reversibility of exhaustion. Upregulation of a single receptor with retained function constitutes reversible exhaustion; simultaneous high expression of multiple receptors with severe loss of function indicates terminal exhaustion.

Set two parallel arms — "antibody replenished" and "no antibody replenishment": the no-replenishment arm tests functional persistence after a single dose (simulating the trough of exposure between dosing intervals), while the replenished arm tests exhaustion tolerance under sustained exposure. A candidate with a large difference between the two arms is sensitive to sustained exposure and requires particularly careful dosing-regimen design. Three to five challenge rounds (7–14 days) are recommended.

Per-round expansion tracking: Record expansion fold and viability at the end of each stimulation round. Expansion capacity is the core readout of durability and a hallmark clinical pharmacodynamic feature of blinatumomab; measuring only phenotype and terminal function without tracking expansion cannot distinguish between the "proliferation-arrest" and "function-decay" failure modes — the remedy for the former is optimizing co-stimulation design, while the remedy for the latter is reducing sustained activation intensity, and the product optimization directions are completely different.

AICD readout: Detect T-cell apoptosis (activation-induced cell death, AICD) by Annexin-V / 7-AAD each round. An apoptosis rate <20% is acceptable; >50–70% indicates that CD3 signaling is too strong and causes structural collapse of T cells — direct evidence of the "proliferation-arrest" failure mode.

T-Cell Subsets and the Tpex/Tex Ratio

The core readout is the Tpex/Tex ratio: after prolonged stimulation, progenitor exhausted T cells (Tpex, TCF-1⁺PD-1⁺) are retained at 20–40%, while terminally exhausted T cells (Tex) are <20–30%. Tpex collapse (<5%) together with a Tex surge (>60–80%) constitutes phenotypic evidence of terminal exhaustion (which must still be combined with functional criteria, see below). Subsetting can use classical gating or dimensionality reduction (t-SNE/UMAP) + clustering; scRNA-seq may be used for deeper resolution when samples allow (optional).

Killing half-life rounds (K₁/₂): Plot the target-cell reduction rate of each challenge round against round number and fit a decay curve to calculate the killing half-life in rounds. K₁/₂ >4 rounds (killing still >70% at round 3); a sharp drop to <20% at rounds 2–3 is classified as the Single-Burst failure mode.

Cytokine polyfunctionality: After each challenge round, assess by intracellular cytokine staining (or supernatant multiplex) the proportion of T cells simultaneously secreting ≥2 effector molecules (IFN-γ / IL-2 / TNF-α / CD107a) — the polyfunctionality index (PI). After multi-round stimulation, the proportion of polyfunctional T cells should remain >20–40%; retention of IL-2 secretion capacity is especially critical (the core factor for T-cell paracrine self-maintenance).

Data Interpretation

Compared with the positive control, a candidate's functional durability is acceptable if, after re-stimulation, it retains killing (retention ≥50%), IFN-γ secretion ≥30% of the first round, and shows positive per-round expansion. High TOX with loss of the TCF-1⁺ population (Tpex/Tex ratio collapse), combined with markedly reduced re-stimulation function, constitutes the evidence chain for terminal exhaustion.

Product list

Product list for this module is being finalized and will be published in a subsequent update.

Blinatumomab Reference Data

• Experimental conditions: T cells + Raji cells (E:T = 10:1), fresh Raji and blinatumomab (1 ng/mL) replenished every 48 h, for 3 rounds (~6 days). Record expansion fold and viability after each round, and measure PD-1, TIM-3, LAG-3, and TIGIT expression; perform re-stimulation at the final round (fresh Raji + blinatumomab, measure killing and IFN-γ at 24 h).

Typical results:

• Round 1 PD-1 positivity approximately 20–30%, rising to 40–60% by round 3; PD-1⁺TIM-3⁺ double-positive proportion usually <35%.
• After re-stimulation, killing is retained at 50–70%, and IFN-γ secretion at 30–50% of the first round.
• Combined anti-PD-1 antibody (10 μg/mL) can partially restore killing function.
• Interpretation benchmark: If a candidate's re-stimulation killing drops >50% by round 3, accompanied by PD-1⁺TIM-3⁺ >40% and expansion arrest, the risk of irreversible exhaustion is high.

Data Validation

The SOLIDEX^®-CDEx immune-checkpoint antibody panel covers key exhaustion markers including PD-1, TIM-3, LAG-3, and OX40. Expected performance in epcoritamab evaluation: over 3 repeated-stimulation rounds (fresh Raji + epcoritamab every 48 h), the GeneMedi negative-selection group is expected to show a lower PD-1⁺TIM-3⁺ double-positive proportion by round 3, with better post-re-stimulation killing retention and IFN-γ secretion than competitor negative-selection groups. Competitor groups, with their starting background activation, are expected to develop exhaustion earlier.

Expected expansion tracking: the GeneMedi group is expected to maintain positive expansion each round, with AICD apoptosis controlled within an acceptable range.